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Abstract
Background: P2X1 receptors play an important role in platelet function as they can induce shape
change, granule centralization and are also involved in thrombus formation. As platelets have no
nuclei, the level of P2X1 expression depends on transcriptional regulation in megakaryocytes, the
platelet precursor cell. Since nothing is known about the molecular mechanisms regulating
megakaryocytic P2X1 expression, this study aimed to identify and functionally characterize the P2X1
core promoter utilized in the human megakaryoblastic cell line MEG-01.
Results: In order to identify cis-acting elements involved in the transcriptional regulation of P2X1
expression, the ability of 4.7 kb P2X1 upstream sequence to drive luciferase reporter gene
expression was tested. Low promoter activity was detected in proliferating MEG-01 cells. This
activity increased 20-fold after phorbol-12-myristate-13-acetate (PMA) induced differentiation. A
transcription start site was detected 365 bp upstream of the start codon by primer extension.
Deletion analysis of reporter constructs indicated a core promoter located within the region -68
to +149 bp that contained two Sp1 sites (named Sp1a and Sp1b) and an NF-1 site. Individual
mutations of Sp1b or NF-1 binding sites severely reduced promoter activity whereas triple
mutation of Sp1a, Sp1b and NF-1 sites completely abolished promoter activity in both untreated
and PMA treated cells. Sp1/3 and NF-1 proteins were shown to bind their respective sites by EMSA
and interaction of Sp1/3, NF-1 and TFIIB with the endogenous P2X1 core promoter in MEG-01 cells
was demonstrated by chromatin immunoprecipitation. Alignment of P2X1 genes from human,
chimp, rat, mouse and dog revealed consensus Sp1a, Sp1b and NF-1 binding sites in equivalent
positions thereby demonstrating evolutionary conservation of these functionally important sites.
Conclusion: This study has identified and characterized the P2X1 promoter utilized in MEG-01
cells and shown that binding of Sp1/3 and NF-1 to elements in the direct vicinity of the transcription
start site is essential for basal transcription. Targeting the function of these transcription factors in
megakaryocytes may therefore provide a basis for the future therapeutic manipulation of platelet
P2X1 function.
Background
P2X receptors comprise a family of membrane cation
channels gated by extracellular ATP. Seven subtypes
(P2X1–7), each encoded for by a separate gene, are present
in mammalian species (reviewed by [1]) and these com-
bine to form either homo or hetero trimeric channels
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[2,3] exhibiting different expression profiles and func-
tional properties. P2X1, the first subtype to be isolated,
was cloned over a decade ago [4] and the physiological
roles of this channel in the regulation of arterial tone [5]
and in the neuronal control of smooth muscle contraction
[6,7] are well established. The presence of P2X1 receptors
in platelets was discovered shortly after its cloning [8,9],
however, it has not been until more recent times that the
physiological importance of P2X1 in platelet function has
started to fully emerge (for review see [10]). Activation of
platelet P2X1 receptors by extracellular ATP results in a
rapid Ca2+ influx which activates cytoskeletal events to
induce a transient but substantial shape change and gran-
ule centralization [11,12], both important early events in
platelet activation. P2X1 receptors can also synergize with
P2Y, collagen, adrenaline and thrombopoietin receptor
mediated responses [10] to enhance platelet function.
Furthermore, over expression of P2X1 in the platelets of
transgenic mice results in a prothrombotic phenotype
[13] whereas an absence of the receptor in P2X1 knockout
mice leads to a reduced risk of thrombosis [14] suggesting
that the level of P2X1 receptor expression in platelets is of
physiological and clinical significance.
Although the physiological roles and consequences of
altered expression levels of platelet P2X1 receptors are
becoming increasingly apparent, the mechanisms that
regulate P2X1 expression in platelets are poorly under-
stood. Since platelets are cell fragments devoid of any
nuclei the complement of channels and receptors present
on their surface must ultimately rely on the regulation of
gene transcription in the megakaryocyte, the platelet pre-
cursor cell. bHLH factors and E proteins are thought to be
involved in smooth muscle specific P2X1 transcription
[15]. Nothing however is known about transcriptional
regulation of P2X1 in megakaryoblastic cells. In order to
initiate studies on the transcriptional mechanisms
involved in determining P2X1 expression levels in plate-
lets, we have identified and characterized the P2X1 pro-
moter in the megakaryoblastic cell line MEG-01 [16]. We
show that Sp1 and NF-1 regulatory elements located in
the direct vicinity of the transcriptional start site are essen-
tial for basal transcription of P2X1 in MEG-01 cells.
Results
Cloning and analysis of the P2X1 gene 5' upstream 
sequence
The human genomic BAC clone RP11-167N20 was found
to contain all 12 exons of the human P2X1 gene and 64 kb
5' upstream sequence. The 4.772 kb upstream of the ATG
start codon was cloned into the pGL-3 Basic luciferase
reporter plasmid to generate the plasmid p-4407/+365
and the sequence analyzed by the Proscan computer pro-
gram [17]. A potential core promoter was predicted at -
151 to +99 bp with a promoter score of 70.32.
The P2X1 transcription start site is located 365 bp 
upstream of the start codon
To map the location of the P2X1 transcription initiation
site in MEG-01 cells, four anti-sense oligonucleotides
Pet1, Pet2, Pet3 and Pet4 (Figure 3) were used for primer
extension. As positive control we utilized a previously
published primer sequence pTXRHR-100 which has been
used to map the transcription start site of the thrombox-
ane receptor gene in MEG-01 cells [18]. Similar to previ-
ous studies, this control primer yielded a single extension
product of ~110 bp (Figure 1A lane 1). A single extension
product of ~210 bp was generated by Pet1 (Figure 1A lane
3), two distinct extension products of ~150 bp and ~249
bp, were generated by Pet3 (Figure 1A lane 5), a doublet
band of ~66 bp was generated by Pet4 (Figure 1A lane 6)
and no extension products were observed from Pet2 (Fig-
ure 1A lane 4). Extension products of 66 bp (Pet4), 150 bp
(Pet3) and 210 bp (Pet1) correspond to a transcription
start site located ~365 bp upstream of the ATG start
codon. The Pet2 sequence is very close to this site (Figure
3) and so would not be expected to produce an extension
product. An additional extension product of 249 bp pro-
duced by the Pet3 primer (Figure 1A, lane 5) indicated the
possibility of an additional transcription start site located
~465 bp upstream of start codon. However, no bands cor-
The P2X1 transcription start site is located 365 bp upstream  of the start codon Figure 1
The P2X1 transcription start site is located 365 bp 
upstream of the start codon. A) 32P-labelled primers 
Pet1, Pet2, Pet3 and Pet4 and Con (control primer 
pTXRHR-100) were annealed to poly(A) RNA from PMA-
treated MEG-01 cells and extended with reverse tran-
scriptase. Extension products for Pet1, Pet3 and Pet4 that 
equate to the same transcription start site are indicated with 
arrows. (M), molecular mass marker. B) Pet3 extension reac-
tion (lane 6) run in parallel with a sequencing ladder. The 
location of primers is depicted in Figure 3.
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responding to such a start site were observed with the
Pet1, Pet2 or Pet4 primers. Furthermore, subsequent anal-
ysis of promoter activity in constructs where this potential
site had been removed (p-111/+149 compared to p-68/
+149 (Figure 2B)) did not indicate the presence of a func-
tional transcription start site in this region. We therefore
attributed the 249 bp band produced by the Pet3 primer
as a non-specific extension product. To precisely map the
start site, sequencing reactions primed with the same Pet
primer used for primer extension were run in parallel to
extension reactions (Figure 1B). The 150 bp Pet3 exten-
sion product (Figure 1B lane 6) corresponds to a transcrip-
tion start site located at a "T" residue 365 bp upstream of
the ATG start codon. This site is 78 bp downstream of the
start site previously described for P2X1 in smooth muscle
[15] but matches closely to the EST clone BX644575
which was isolated from human bone marrow, a tissue
rich in megakaryocytes.
PMA induced differentiation results in a 20-fold increase in 
P2X1 reporter gene activity
In initial studies, we tested the p-4407/+365 construct for
promoter activity in three cell lines previously reported to
show endogenous P2X1 expression, MEG-01 [9,19], HL-
60 [20] and Jurkat [21]. The human kidney proximal
tubular epithelial cell line HK2 was used as negative con-
trol. Cells were assayed both with and without prior treat-
ment with PMA, a phorbol ester previously reported to
increase P2X1 mediated currents in MEG-01 [9,19] and
HL-60 [20] cells. Low promoter activity was detected in
untreated MEG-01, HL-60 and Jurkat cells but not in HK2
cells (Figure 2A). Treatment of MEG-01 cells with 10 nM
PMA caused cells to differentiate to a non-proliferating
adherent phenotype and resulted in a ~20 fold increase in
promoter activity of p-4407/+365. This PMA-induced
increase was also apparent in Jurkat and HL-60 cells but
not in HK2 cells (Figure 2A). Comparisons of promoter
activity between different constructs in untreated MEG-01
cells proved problematic since promoter activities were
not sufficiently above background to allow accurate quan-
tification. PMA-differentiated MEG-01 cells were there-
fore utilized for subsequent analysis since these cells
represent a well characterized model of megakaryocyte
maturation [22] and the higher P2X1 promoter activity
aided quantification of differences between constructs.
Deletion analysis of luciferase reporter gene constructs
To define the mechanisms controlling transcriptional reg-
ulation of P2X1 in MEG-01 cells, a series of deletion con-
structs were generated. Gradual deletion of 5' sequence
from -4407 to -2235 resulted in no significant change in
luciferase activity (Figure 2B) suggesting that no impor-
tant regulatory elements reside in this ~2 kb region.
Removal of sequence between -2235 and -1398 in con-
struct p-1398/+365 however resulted in a 88 ± 14%
increase (p < 0.01) in promoter activity indicating the
presence of a repressive element. Sequence analysis of this
region revealed a 396 bp polypyrimidine tract located -
1801 to -1405 bp which contains 15 copies of the
sequence motif 5'-TCCCTCCCTCCC-3'. Interestingly, this
same sequence motif is present in the mouse c-Ki-ras pro-
moter where it plays a role in transcriptional regulation
[23]. Within this polypyrimidine tract region are clustered
multiple potential Sp1, Ets-2 and MAZ transcription fac-
tor binding sites. The increase in promoter activity was
maintained throughout deletions from 1398 to 190 in the
constructs p-805/365, p-454/+365, p-330/+365, and p-
190/+365 (p < 0.01 for each construct) (Figure 2B). The
difference in promoter activity between constructs p-
1398/+365 through to p-190/+365 was not significant.
Removal of 3' sequence from +365 to +149 bp (p-190/
+149) decreased promoter activity back to the level of the
p-4407/+365 construct. Deletion of 5' sequence from -
190 to -111 bp (p-111/+149) resulted in a 63 ± 5%
Activity of P2X1 promoter constructs in transient transfec- tion assays Figure 2
Activity of P2X1 promoter constructs in transient 
transfection assays. A) Promoter activity of p-4407/+365 
was determined both with (+) and without (-) the prior 
treatment of cells with 10 nM PMA. Data are means of abso-
lute firefly luciferase activity of three independent transfec-
tions. B) Luciferase activity of P2X1 deletion constructs in 
PMA treated MEG-01 cells. TSS, transcription start site. PT 
depicts a polypyrimidine tract located from -1801 to -1405 
bp. Values are presented as means of at least three experi-
ments and normalized against the construct p-4407/+365. 
Names of plasmid constructs correspond to the 5' and 3' 
ends of the insert relative to the transcription start site e.g. 
construct p-4407/+365 extends from 4407 bp 5' to 365 bp 3' 
of the transcription start site.
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decrease (p < 0.01) in promoter activity. Further deletion
of 43 bp 5' sequence in construct p-68/+149 produced no
significant change in activity from p-111/+149. Removal
of 3' sequence however from +149 to +17 bp in construct
p-190/+17 completely abolished promoter activity.
Thus, to summarize the deletion analysis performed on
the P2X1 upstream region, promoter activity was stable or
increased in 5' deletions from -4407 through to position -
190. Deletions past -190 up to position -68 significantly
reduced promoter activity whereas removal of 132 bp
from +149 to +17 bp abolished promoter function dem-
onstrating that this region contains regulatory elements
essential for transcription.
In vitro binding of Sp1/3 and NF-1 to the P2X1 promoter
Results from the above deletion analysis suggested that
the region -190 to +149 bp plays an important role in the
transcriptional regulation of the P2X1 gene (Figure 3).
Analysis of this region using the programmes TESS [24]
and PROSCAN [17] did not reveal putative TATA or
CCAAT boxes, but detected several potential transcription
factor binding sites including NF-κB, YY-1, GATA-1, NF-1,
and multiple Sp1 sites. To begin to understand which spe-
cific transcription factors are involved in regulating P2X1
gene transcription we initially performed EMSAs on
nuclear extracts from PMA-treated MEG-01 cells using oli-
gonucleotides corresponding to a potential NF-1 site and
two Sp1 sites (named Sp1a and Sp1b) located in the
immediate vicinity of the transcription start site. The radi-
olabelled probe O-NF1 containing a potential NF-1 bind-
ing site produced a major retarded band (Figure 4A lanes
1 and 3), the formation of which was prevented by an
excess of unlabelled O-NF1 itself (Figure 4A lane 4) but
not by the mutated O-NF1-mut probe (Figure 4A lane 5).
In the presence of an anti-NF-1 antibody, the DNA-pro-
tein complexes were either supershifted or remained in
the well (Figure 4A lane 2). Similar results for NF-1 super-
shift complexes have also been reported in previous stud-
ies [25,26], we therefore concluded that NF-1 can bind to
the P2X1 proximal promoter.
The probes O-Sp1a and O-Sp1b corresponding to the
Sp1a and Sp1b binding sites respectively, gave rise to three
major DNA-protein complexes, the larger two of which
appear as a doublet band (Figure 4B lanes 1 and 4). To
identify specific transcription factor binding, supershift
assays with Sp1 and Sp3 antibodies were performed. The
Sp3 antibody produced a supershift ("ss" Figure 4B lanes
3 and 6). Sp1 antibodies caused a decrease in intensity of
the doublet band but produced no visible supershifted
products (Figure 4B lanes 2 and 5). To further clarify the
molecular basis of Sp1/Sp3 interactions with the oligonu-
cleotide probes, competition experiments were performed
(Figure 4C). Addition of unlabelled O-Sp1a or O-Sp1b
prevented binding of Sp1/Sp3 to labelled probe (Figure
4C lanes 2 and 6). Similarly, addition of an unlabelled
commercial consensus Sp1 oligonucleotide (Figure 4C
lanes 4 and 8) also prevented Sp1/Sp3 binding to O-Sp1a
and O-Sp1b. In contrast O-Sp1a-mut and O-Sp1b-mut
did not prevent protein binding (Figure 4C lanes 3 and 7)
demonstrating that a 2 bp mutation (Table 1) disrupted
Sp1/3 binding.
An oligonucleotide probe corresponding to the potential
NF-κB binding site (O-NFκB) did not produce super-
shifted products after addition of an NF-κB antibody (data
not shown). In summary EMSAs demonstrated that Sp1,
Sp3 and NF-1 transcription factors can bind regulatory
elements in the P2X1 proximal promoter implying that
these factors are involved in the regulation of P2X1 gene
transcription.
Sequence of the P2X1 proximal promoter region Figure 3
Sequence of the P2X1 proximal promoter region. 
Potential transcription factor binding sites are underlined and 
in bold. Oligonucleotide sequences used for primer exten-
sion analysis (Pet1-4) are indicated by horizontal arrows. End 
points of plasmid deletion constructs in this region are indi-
cated by "p" and number above the sequence. Sequence 
numbering is relative to the transcription start site indicated 
as +1. The translation initiation ATG is boxed. The EMBL/
Genbank accession number of this sequence is AJ971536.
GTCTCATTTTGGCAGTGGAGGGGAGTCGCGGGGAGTCCC
CTAATCTGAGGAGACTCCAGCTTCCCCCAGGCCCTGGCC
AGAGCTCCATCTTGCCAGGTTTTGGGGGGAGGATAACTT
GAGGAGTCGACTGAGAGCTTTATCTTTGCCCCTGTGACG
GGTGGCCTGTGGTTTCCTGCCAACAACTCCTGTTTCCGG
AGGCCCAACAAGGCCCACGCAGAGCCAGGAGGGGCAGTG
GGGCTGGGCCTGGGTGGCCCCACCAGCCCCGCCCCATCT
ATCTTTGGGAATTTATTTGTCCATGGGCGAGGCTGGCCT
GCAGTCTGTTGCCTTCCAGGGGCCAAGAGCTGCTCTGAT
CACCCAGGGATTCTCTCTCCAACCCAAGTGCCTCCAGCT
GACCTCTGGCTCCTGTCCTCTGGCTCCACCTGCACCGCC
CTGCTCTTCCTAAGGGGCCAGGAAGCCCCCAGAAGCTCT
ACCATCGACGTGGGTGGTGGCACCCGGCTCACCCTGAGA
GCAGAGGCCGTGCAGGGGGCTCAGTTCTGAGCCCCAGCC
GGCCCACCATG
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Sp1 and NF-1 sites are essential for basal transcription of 
the P2X1 gene
We next conducted site-directed mutagenesis to disrupt
the Sp1/3, NF-1 and NF-κB binding sites in selected P2X1
promoter constructs. Promoter activity of mutated con-
structs was determined in PMA treated MEG-01 cells and
expressed relative to that of the wild type p-190/+149 con-
struct (Figure 5). Single mutation of the NF-κB (construct
mNF-κB) and Sp1a (construct mSp1a) sites produced no
significant change in promoter activity (Figure 5A). Single
mutation of the NF-1 site (construct mNF-1) or Sp1b site
(construct mSp1b) however resulted in 76 ± 5% (p <
0.01) and 76 ± 2% (P < 0.01) reductions respectively. A
double mutation ablating both NF-1 and NF-κB sites
simultaneously (construct mut1) reduced promoter activ-
ity by 80 ± 2% (p < 0.01), whereas double mutation of
Sp1a and Sp1b sites (construct mut2) reduced activity by
92% ± 1 (p < 0.01). Simultaneous mutation of NF-1 and
Sp1b sites (construct mut3), the NF-1 site together with
Sp1a and Sp1b sites (construct mut4), or deletion of the
fragment from +18 to +149 bp which removes both Sp1a
and Sp1b sites (construct p-190/+17) effectively abol-
ished promoter activity (Figure 5A).
In order to confirm the apparent redundancy of the poten-
tial NF-κB site, we generated a further set of mutations in
the plasmid p-111/+149, a construct where the potential
NF-κB site has been removed (Figure 5B). Whilst removal
of 79 bp from -190 to -111 resulted in a ~50% decrease in
promoter activity, the overall pattern of promoter activity
resulting from Sp1 and NF-1 binding site mutations was
very similar to that observed in the p-190/+149 mutations
(Figure 5A).
A P2X1 transcription start site 78 bp upstream from site
identified in this current study has been reported in
human smooth muscle cells [15]. If this same site is uti-
lized in MEG-01 cells then its removal in deletion con-
structs would be expected to abolish promoter activity. To
test this hypothesis and to further delineate a functional
core promoter, the construct p-68/+149 was generated. p-
68/+149 displayed a promoter activity 32 ± 3% that of the
p-190/+149 construct. Single and double site-directed
mutations of Sp1 and NF-1 binding sites in this p-68/
+149 construct again showed a similar pattern of pro-
moter activity to that observed in the p-190/+149 con-
struct (Figure 5C).
From the above mutation and previous deletion analysis,
we defined the region spanning -68 to +149 as the P2X1
core promoter composing of a single NF-1 binding site
and two Sp1-binding sites. To prove the importance of
these sites in controlling basal transcription, the Sp1a,
Sp1b and NF-1 sites were mutated in the original 4.7 kb
reporter construct p-4407/+365 to generate the construct
p-4407/+365(mut4). Promoter activity from this triple
mutated construct was abolished in both untreated and
PMA-treated MEG-01 cells (Figure 5D) confirming the
essential roles of Sp1 and NF-1 in P2X1 basal transcrip-
tion.
Direct binding of Sp1/3 and NF-1 to the endogenous P2X1 
core promoter
Having identified Sp1, Sp3 and NF-1 sites essential for
P2X1 reporter gene function, we next utilized ChIP to
determine whether the corresponding transcription fac-
tors are physically recruited to the endogenous P2X1 core
promoter in vivo (Figure 6). Primers for the Hsp70 and his-
tone H4 promoters were used as positive controls as Sp1
and Sp3 have previously been detected at these promoters
by ChIP assay [27,28]. As a negative control, parallel
experiments using primers for the coding region of the
GAPDH gene were performed. Antibodies for Sp1, Sp3,
NF-1 and TFIIB in ChIP assays using chromatin isolated
EMSA assays on NF-1 and Sp1/Sp3 binding sites Figure 4
EMSA assays on NF-1 and Sp1/Sp3 binding sites. A) 
Competition experiments were performed in the presence 
of excess unlabelled O-NF1 (lane 4) and unlabelled mutated 
O-NF1-mut (lane 5). Complexes supershifted by pre-incuba-
tion with an NF-1 antibody (NF-1Ab, lane 2) are marked 
"SS". "NS" indicates non specific binding complexes, the level 
of which varied between individual nuclear extractions (lanes 
1 and 3). "F" indicates free probe. B) Supershift assays using 
Sp1 (lanes 2 and 5) and Sp3 (lanes 3 and 6) specific antibod-
ies. C) Competition experiments in the absence (lanes 1 and 
5) or presence of excess of unlabelled competitors: Lanes 2 
and 6, an excess of unlabelled O-Sp1a or O-Sp1b probe 
respectively. Lanes 3 and 7, an excess of unlabelled mutated 
oligonucleotide O-Sp1a-mut and O-Sp1b-mut respectively. 
Lanes 4 and 8, an excess of a consensus Sp1 oligonucleotide 
(Promega, E323A).BMC Molecular Biology 2006, 7:10 http://www.biomedcentral.com/1471-2199/7/10
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from PMA-treated MEG-01 cells resulted in enrichment of
the DNA genomic segment harboring the region -197/
+166 of the P2X1 gene thus confirming the in vivo recruit-
ment of these factors to the core promoter.
Discussion
Regulation of P2X1 transcription in megakaryocytic cells is
of physiological and clinical importance as ultimately this
will influence the level of P2X1 receptor present on plate-
lets, excessive activation of which can lead to thrombosis,
cardiovascular disease and stroke. As a first step towards
understanding the transcriptional mechanisms regulating
P2X1 expression in megakaryocytic cells, we have analyzed
the P2X1 promoter in MEG-01 cells. We identified a tran-
scription start site 365 bp upstream of the start codon and
defined a core promoter located within the region -68 to
+149 bp. Two Sp1 sites and an NF-1 site in the core pro-
moter were shown to be critical for basal transcription.
The P2X1 core promoter was found not to possess "TATA"
or "CCAAT" elements but contained Sp1 and NF-1 sites
critical for basal transcription. Mammalian promoters
lacking a TATA box often contain Sp1 elements and rely
on Sp1 to recruit TATA-binding protein and guide RNA
polymerase II to the initiator site [29-31]. Sp1 and Sp3 are
members of a large family of transcription factors that reg-
ulate transcription through interactions with GC-boxes.
They are both zinc finger proteins that bind the same DNA
recognition sequences with similar affinity [32]. Despite
ubiquitous expression, tissue-specific gene activation by
Sp1 and Sp3 may be achieved by a variety of mechanisms
including variability in the concentration of Sp1 and Sp3
[32], interactions of Sp1 with tissue specific transcription
factors [33] and tissue specific post-translational modifi-
cation of Sp1 and Sp3 [32]. Sp1/3 can regulate gene tran-
scription through a variety of mechanisms, functioning as
either a basal promoter element or an upstream activator,
depending on promoter [34,35]. Two Sp1/3 sites were
identified in the P2X1 promoter and mutation of the Sp1b
(+71 to +79) site most markedly reduced promoter activ-
ity. Single mutation of the Sp1a (+44 to +52) site did not
significantly reduce transcription. However, simultaneous
mutation of both Sp1a and Sp1b together entirely abol-
ished transcriptional activity. Thus, the Sp1b site can com-
pletely compensate for the loss of the Sp1a site but Sp1a
can only partially compensate for the loss of Sp1b suggest-
ing that whilst both sites may be utilized in basal tran-
scription, the Sp1b site plays a more prominent role.
An NF-1 site in the P2X1 core promoter was also found to
be important for transcription. NF-1 proteins are recruited
to promoters in a cell type specific manner and can asso-
Table 1: Oligonucleotides used for EMSA. Primer sequences are 5' to 3'. Bold lowercase bases represent mutations with respect to the 
wild type sequence. Underlined sequences represent consensus binding sites for respective transcription factor.
Name Position Sequence
O-NFκB -168/-144 GAGTCGCGGGGAGTCCCCTAATCTG
O-NFκB-mut GAGTCGCGGccAGTCCCCTAATCTG
O-NF1 -29/-5 CCTGTGGTTTCCTGCCAACAACTCC
O-NF1-mut CCTGTGGTTTCCTtaaAACAACTCC
O-Sp1a +33/+60 GGAGGGGCAGTGGGGCTGGGCCTGGGT
G
O-Sp1a-mut GGAGGGGCAGTGGttCTGGGCCTGGGT
G
O-Sp1b +63/+90 CCCACCAGCCCCGCCCCATCTATCTTTG
O-Sp1b-mut CCCACCAGCCCCGaaCCATCTATCTTTG
Table 2: Binding site mutants. Positions of mutations in mutant constructs. Schematic illustration of the P2X1 core promoter mutation 
constructs. "." indicates positions same as wild type. "~" indicates where sequence has been omitted for clarity.
NF-κB NF-1 Sp1a Sp1b
Wild type GGGGAGTCCCC~~~TGGTTTCCTGCCAAC~~~GGGGCTGGG~~~CCCCGCCCC
mNFkB ..CC.......~~~...............~~~.........~~~.........
mNF-1 ...........~~~.........TAA...~~~.........~~~.........
mSp1a ...........~~~...............~~~..TT.....~~~.........
mSp1b ...........~~~...............~~~.........~~~.....AA..
mut1 ..CC.......~~~.........TAA...~~~.........~~~.........
mut2 ...........~~~...............~~~..TT.....~~~.....AA..
mut3 ...........~~~.........TAA...~~~.........~~~.....AA..
mut4 ...........~~~.........TAA...~~~..TT.....~~~.....AA..BMC Molecular Biology 2006, 7:10 http://www.biomedcentral.com/1471-2199/7/10
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ciate with different regulators to either activate or repress
transcription depending on the promoter and cellular
context [36,37]. Site-directed mutagenesis of the NF-1 site
in the P2X1 core promoter significantly reduced transcrip-
tional activity by ~80% (Figure 5). Simultaneous muta-
tion of both NF-1 and Sp1b sites completely abolished
promoter activity suggesting that NF-1 and Sp1/3 may act
synergistically to recruit the initiation complex to the P2X1
core promoter.
The human P2X1 promoter identified in this study shows
characteristics typical of those normally associated with
housekeeping genes: lack of classical TATA or CCAAT
boxes, an increased GC content and critical Sp1 and NF-1
elements [38]. This would appear ideally suited for P2X1
expression in megakaryocytes since constant synthesis is
required for platelet production. Constitutive expression
of P2X1 however does not occur in all hematic cell types
and their progenitors as neutrophils, monocytes and lym-
phocytes show no significant expression of P2X1 [39,40].
This suggests that tight repression of the P2X1 promoter
occurs and that release from this repression may be an
important feature of P2X1  transcriptional regulation.
Deletion analysis performed in this study identified a
repressive element in an upstream region containing a
396 bp polypyrimidine tract located -1801 to -1405.
Removal of this tract in deletion constructs p-1398/+365
through to p-190/+365 resulted in a ~90–100% increase
in promoter activity (Figure 2B). Polypyrimidine tracts
can harbor multiple binding sites for Sp1 and Sp3 [41,42]
and play important roles in the regulation of gene tran-
scription [43,44]. A possible mechanism for the repressive
effect of the P2X1 polypyrimidine tract could be that this
region facilitates a local sequestration of Sp1/3 factors
hindering their binding to the Sp1a and Sp1b sites further
downstream in the core promoter.
Important transcriptional regulatory elements often show
conservation between species [45]. We therefore investi-
gated whether the NF-1, Sp1a and Sp1b binding sites
identified in the human promoter are also present in the
upstream sequence of P2X1  genes from other species.
Using BLAST searches of genomic sequence data we iden-
tified P2X1 genes from mouse, chimp, dog and rat. Similar
to human, the upstream regions of these genes were also
GC-rich and contained no "TATA" or "CCAAT" elements.
Sequence alignment revealed NF-1, Sp1a and Sp1b sites in
identical positions across all species examined (Figure 7).
These results demonstrate a conserved core promoter
structure in mammalian P2X1 genes and suggest that the
involvement of Sp1/3 and NF-1 in the regulation of P2X1
transcription has been conserved during evolution.
PMA-induced differentiation of MEG-01 cells is widely
used as a model of megakaryocytic maturation and is
known to increase the expression of megakaryocytic line-
age specific antigens, such as integrin αIIbβ3 [22,46]. PMA
activates signaling cascades via activation of PKC and
other C1 domain containing receptors resulting in a wide
range of cellular effects [47]. PMA can enhance P2X1
mediated responses in MEG-01 [19], THP1 [39], and HL-
60 [20] cells and is also thought to have more acute effects
by increasing phosphorylation of a putative P2X1 acces-
sory protein [48]. In this study, we found that P2X1 pro-
moter activity increased ~20-fold in PMA-differentiated
MEG-01 cells compared to untreated cells. Several studies
have shown Sp1 DNA-binding activity and expression
level to increase upon treatment of cells with PMA [49-
53]. Similarly, PMA induction has been shown to increase
the formation of NF-1 DNA complexes [54,55]. We there-
fore speculate that PMA enhances P2X1 ion channel func-
tion through the actions of Sp1 and NF-1 at the P2X1 core
promoter resulting in an increase in gene transcription
and the synthesis of new P2X1 protein. The signaling path-
ways that link PMA stimulation with P2X1 gene activation
and whether these result in alterations in the levels of Sp1
and NF-1 or in protein modifications such as phosphor-
ylation altering the affinity of factors for their respective
binding sites remain to be determined.
Table 3: Oligonucleotides used for ChIP analysis. Primer sequences are 5' to 3'. At the end of oligonucleotide names, f: indicates a 
sense primer, r: indicates an antisense primer.
Name Sequence Product size
P2X1f CGCACGCGTTCTCATTTTGGCAGTGGAG
GGGAG
360 bp
P2X1r GGTGATCAGAGCAAAGCTTGGCCCCTG
G
Hsp70f CCTCCAGTGAATCCCAGAAGACTCT 282 bp
Hsp70r TGGGACAACGGGAGTCACTCTC
H4f GAGAGGGCGGGGACAATTGA 362 bp
H4r TTGGCGTGCTCGGTGTAGGT
GAPDHf TGAAGGTCGGAGTCAACGGATTTGGT 983 bp
GAPDHr CATGTGGGCCATGAGGTCCACCACBMC Molecular Biology 2006, 7:10 http://www.biomedcentral.com/1471-2199/7/10
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Conclusion
The in vivo control of P2X1 transcription in megakaryo-
cytes is undoubtedly a complex combinatorial process
involving the integration of a large number of protein-
protein and protein-DNA interactions that mediate cell
type specific expression during megakaryocyte differentia-
tion and the ability respond to regulatory inputs. This
study provides the first steps towards unraveling the com-
plexities of this control by providing the fundamental
information of P2X1 core promoter location and compo-
sition in a megakaryocytic cell line. We demonstrate that
Sp1 and NF-1 are critical for P2X1 core promoter function
in both proliferating and PMA-differentiated MEG-01
cells. The targeting of signaling pathways that influence
the function of these transcription factors in megakaryo-
cytes may therefore provide the basis for the future thera-
peutic manipulation of platelet P2X1 function.
Methods
Reporter constructs
The human genomic BAC clone (RP11-167N20) contain-
ing the human P2X1 gene was obtained from the Sanger
Institute. 4.772 kb upstream of the start codon was ampli-
fied by PCR using Pfu polymerase (Promega, Madison,
WI) and cloned into pGL3-Basic (Promega). A series of 5'
deletion constructs were created either by restriction
Mutation analysis of transcription factor binding sites Figure 5
Mutation analysis of transcription factor binding 
sites. A series of luciferase reporter constructs harbouring 
site-directed mutations in the NF-κB, NF-1 and Sp1 binding 
sites of the P2X1 proximal promoter region were assayed for 
promoter activity in PMA-treated MEG-01 cells (sequences 
of mutations are shown in Table 2). Shaded symbols repre-
sent mutated binding sites. Values are presented as means ± 
S.E of at least three independent experiments and are nor-
malized against the wild type p-190/+149 construct for pan-
els A to C and the wild type construct p-4407/+365 in panel 
D. A) Effects of mutations in the construct p-190/+149. B) 
Effect of mutation after removal of the potential NF-κB bind-
ing site. C) Effect of mutation after removal of the transcrip-
tion start site that is utilized by smooth muscle cells [15]. 
Dotted vertical arrow (TSS) represents the transcription 
start site determined in this study. D) The Sp1a, Sp1b and 
NF-1 sites were mutated in the original full length 4.7 kb 
reporter construct p-4407/+365 to generate the triple 
mutated construct p-4407/+365(mut4). Promoter activities 
were determined in MEG-01 cells either treated (+) or 
untreated (-) with PMA.
Transcription factors bind the endogenous P2X1 promoter Figure 6
Transcription factors bind the endogenous P2X1 pro-
moter. Formaldehyde cross-linked chromatin was prepared 
from PMA-treated MEG-01 cells and immunoprecipitated 
with antibodies to Sp1 (lane 4), Sp3 (lane 5), NF-1 (lane 6), 
TFIIB (lane 7), or in the absence of antibody (lane 3). PCR 
was performed with specific primers for the P2X1, H4 and 
Hsp70 promoter and for the GAPDH coding region as a nega-
tive control. A sample representative of the total input chro-
matin (input DNA lane 1) was included in the PCR analysis. 
Lane 2 shows the supernatant of the 'unbound' sample. PCR 
products were between 282 and 983 bp in length. PCR cycle 
numbers were 31 for the P2X1, H4 and Hsp70 promoter and 
36 for the GAPDH coding region. Primer sequences are given 
in Table 3.
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enzyme digestion with Mlu I/Hind III or via a PCR based
approach to introduce Mlu I/Hind III sites via primers.
Cell culture
MEG-01, HL-60 and Jurkat cells were purchased from the
German National Resource Centre for Biological Material
(DSMZ) and maintained at 37°C in 5% CO2 in RPMI
1640 medium supplemented with 10% heat-inactivated
fetal bovine serum. HK2 cells were maintained in Dul-
becco's modified Eagle's medium-Ham's F12 mix supple-
mented with 10% fetal bovine serum and 2 mM L-
glutamine.
Site-directed mutagenesis
Point mutations were introduced into potential Sp1 and/
or NF-1 binding sites by a two step cloning strategy. A 339
bp fragment (spanning from -190 to +149 bp) was cut
from the P2X1 pGL3-Basic plasmid, cloned into the Mlu I/
Hind III sites of pCR-Script™ and used as template for
mutagenesis using the QuikChange™ system (Stratagene,
La, Jolla CA). Mutated fragments were then re-cloned into
the Mlu I/Hind III sites of the corresponding pGL3-Basic
vectors. Double (mut1, mut2 and mut3) and triple-site
(mut4) mutation constructs were generated by consecu-
tive rounds of mutagenesis. The triple mutation construct
p-4407(mut4) was generated by replacing a Sal I/Hind III
fragment with the equivalent mutated Sal I/Hind III frag-
ment from the plasmid mut4.
Mapping the P2X1 transcription start site
Poly(A) RNA was isolated from PMA (10 nM) treated
MEG-01 cells using RNAWIZ™ total RNA and Poly(A) Pur-
ist™ mRNA purification kits (Ambion, Austin, TX). Exten-
sion of [γ-32P]ATP labeled primers (Figure 1) was
performed using the Promega Primer Extension System
(Promega, E3030). Size of extension products was deter-
mined by resolution on denaturing 8% polyacrylamide
gels. Locations of the primers used are depicted in Figure
3.
Transient transfection and luciferase assays
For transient transfections 5 × 104 cells were plated in 96-
well plates and incubated with 80 ng of P2X1 reporter
plasmid, 20 ng of pRL-SV40 and 0.3 µl of transfection rea-
gent (GeneJuice™, Novagen Madison, WI). The Renilla
luciferase plasmid pRL-SV40 (Promega) was used as inter-
nal control for transfection efficiency. Following transfec-
tion, cells were cultured in the absence or presence of 10
nM PMA. The Dual-Glo™ Luciferase Assay (Promega) was
used to determine firefly and renilla luciferase activity 48
Cross species conservation of the P2X1 core promoter Figure 7
Cross species conservation of the P2X1 core promoter. P2X1 upstream sequence from chimp (chromosome 19 position 
4051445–4051944), dog (chromosome 9 position 40295005–40295504), rat (chromosome 10 position 59889637–59890136) 
and mouse (chromosome 11 position 72611373–72611872) was obtained by BLAST searching of genomic databases via the 
ENSEMBL genome browser http://www.ensembl.org. The 500 bp upstream of the ATG start codon of each gene was aligned 
using CLUSTAL. Alignment equivalent to -68/+149 of the human P2X1 core promoter is shown. Sequence identity to the 
human P2X1 sequence over this region was 99.1%, 83.4%, 76.8%, and 75.9% for chimp, dog, mouse and rat respectively. "." indi-
cates nucleotides identical to the human P2X1 sequence. Dashes indicate positions where gaps have been inserted in order to 
maintain the alignment. The transcription start site of the human P2X1 gene determined in this study is indicated as +1. Poten-
tial transcription start sites predicted by PROSCAN [17] are indicated as arrows. In each species, potential NF-1, Sp1a and 
Sp1b binding sites (indicated by boxes) are present in equivalent positions to the human P2X1 core promoter.
      -68                                                                    +1      +9
Human GTCGA-CTGAGAGCTTTATCTTTGCCCCTGTGACGGGTGGCCT--GTGGTTTCCTGCCAACAACTCCTGTTTCCGGAGGC
Chimp .....-.....................................--...................................
  Dog .--.......T.............-----A..---.......C--.................G..........T......
Mouse ..--...CAGT.............G.......G.T.......ATG.........G.AG.G..G.................
  Rat ..--...CAGT.............G.......G.T.......ATG...........AG.G..G.................
      +10                                                                            +8
Human CCAACAAGGCCCACGCAGAGCCAGGAGGGGCAGTGGGGCTGGGCCTGGGTGGCCCCACCAGCCCCGCCCC-ATCTATCTT
Chimp ......................................................................-G........
  Dog T..G.........G..G.......AC..A.C.A.........................................C.....
Mouse ...G.........G..G.....TT......T.......................T...TG..T.....T.TG........
  Rat ...G.........G..G.....TAA.....T.......................T...TG..T.....T.TG........
      +89                                                         +149
Human TGGGAATTTATTTGTCCATGGGCGAGGCTGGCCTGCAGTCTGTTGCCTTCCAGGGGCCAAG
Chimp ..........................................................C..
  Dog ..................CA....C........CA.....CA.C....G...A........
Mouse .............CA...G....ACCA......G.T.C..CAC.....G....CA.T...A
  Rat .............CA........ACCA.G....G.T.C..CAC.....G....CA.....A
NF-1
Sp1a                                     Sp1bBMC Molecular Biology 2006, 7:10 http://www.biomedcentral.com/1471-2199/7/10
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hours after transfection in 96-well plates. Firefly luciferase
activity was normalized to Renilla activity in each trans-
fection. All plasmids were purified using Qiagen columns
(Qiagen, Valencia CA) and at least two preparations per
plasmid were tested. Transfections were done in triplicate
in each experiment and at least 3 experiments were per-
formed for each construct. Data are presented as means of
experiments ± Standard error. Differences between means
of control and experimental constructs were assessed by
Dunnett's test. Differences between experimental con-
structs within a dataset were assessed using Tukey's multi-
ple comparison test.
Electrophoretic mobility shift assays
Nuclear proteins were isolated from PMA-treated (10 nM,
48 hours) MEG-01 cells essentially as described by Hurst
[56]. EMSAs were performed using the Promega EMSA kit
on at least three different preparations of nuclear extract
for each experiment. Bands that could not be competed by
cold unlabelled oligonucleotide, consensus oligonucle-
otide or the non-specific competitor Poly dI-dC were
classed as non-specific binding complexes. Nuclear pro-
tein (5.0 µg) was incubated with or without a 100-fold
molar excess of unlabelled competitor DNA in 4% glyc-
erol, 1 mM MgCl2, 0.5 mM dithiothreitol, 0.5 mM EDTA,
50 mM NaCl, 10 mM Tris-HCl, pH 7.5 and 2.0 µg poly
(dI-dC) on ice for 15 minutes, followed by addition of the
radiolabelled probe. For supershift assays, antibodies
(Santa Cruz Biotechnology Inc, Santa Cruz, CA) were
added to the reaction mixture 25 minutes prior to the
probe. DNA-protein complexes were resolved by electro-
phoresis on 6% polyacrylamide gels. Commercial double-
stranded oligonucleotides used were as follows: Sp1, 5'-
ATTCGATCGGGGCGGGGCGAGC-3', (Promega); NF-1,
5'-TTTTGGATTGAAGCCAATATGATAA-3' (Santa Cruz).
Other oligonucleotide sequences are shown in Table 1.
Chromatin Immunoprecipitation
Formaldehyde cross-linking and chromatin immunopre-
cipitation were performed as described by Okada and co-
workers [57]. After PMA treatment for 48 hours, 2 × 106
cells were treated with formaldehyde for 10 minutes fol-
lowed by the addition of 0.125 M glycine. Cells were
washed twice in PBS and re-suspended in lysis buffer (1%
SDS, 10 mM EDTA, 50 mM HEPES, 10 µl/ml Protease
inhibitor Cocktail (Sigma) adjusted to pH 7.9 with KOH).
After sonication to an average fragment size of 500 bp,
protein-DNA cross-linked products were enriched by
immunoprecipitation. Samples without antibody were
included as negative controls. After reversal of cross links
and DNA purification, the extent of enrichment was mon-
itored by PCR using primers to P2X1, H4, and Hsp70 pro-
moter fragments and to the coding region of GAPDH as
negative control. The input sample was processed with the
rest of the samples from the point at which the cross links
were reversed.
Abbreviations
EMSA, electrophoretic mobility shift assay; PMA, phor-
bol-12-myristate-13-acetate; S.E, standard error; ChIP,
chromatin immunoprecipitation.
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